ArticleInternational journal of nanomedicine2026
cGAMP-Loaded M2e Nanovaccine Elicits Cross-Reactive Immunity and Mitigates H6N1 Avian Influenza Infection in Chickens.
Article in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Avian influenza virus (AIV) is a rapidly evolving zoonotic pathogen that causes significant economic loss in the poultry industry and threatens public health. In the development of a broadly protective influenza vaccine, the extracellular domain of matrix protein 2 (M2e) is a promising antigen candidate as it is highly conserved across most influenza A subtypes. M2e-induced immune protection is primarily mediated through antibody-dependent cellular cytotoxicity (ADCC), which enables the clearance of infected cells before viral release. However, the immunogenicity of M2e is limited due to its small size and low abundance on the viral surface, necessitating effective antigen delivery systems to enhance its presentation. Methods: We developed a PLGA-based nanoshell vaccine co-encapsulating M2e peptide and a STING agonist and evaluated its immunogenicity and protective efficacy in specific-pathogen-free (SPF) chickens. Results: Immunization of SPF chickens with the M2e nanoshell vaccine significantly enhanced immune-related gene expression and B-cell expansion, leading to a robust and durable M2e-specific antibody response. In addition, the induced antibodies demonstrated cross-reactivity by effectively recognizing the M2e protein expressed on MDCK cells infected with seven different strains of influenza viruses. Following H6N1 challenge, vaccinated chickens showed attenuated lesions in the kidneys and decreased viral load and viral antigen in the respiratory and intestinal lymphoid tissues, suggesting reduced viral replication. Furthermore, to explore potential Fc-mediated effector functions, an in vitro killing assay demonstrated that chicken splenic natural killer cells were capable of lysing influenza-infected target cells in the presence of serum from M2e nanoshell-immunized chickens, providing initial functional evidence of ADCC activity in the avian system. Conclusion: Collectively, these results demonstrate that the M2e nanoshell vaccine elicits durable and cross-reactive immune responses and reduces tissue damage, potentially involving ADCC-mediated effector mechanisms. The M2e nanoshell vaccine shows potential as a broadly protective avian influenza vaccine and holds value for controlling AIV outbreaks in poultry.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.